NCT07885306
Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment increased: 9 → 10 participants
- Minor Study sites: 2 to 4
- Secondary endpoints revised (5)
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Dose-Limiting Toxicities
Timeframe: From the first dose through Day 28
Secondary (5)
Treatment-Related Adverse Event
Objective Response Rate
Disease Control Rate
Progression-Free Survival
Overall Survival
Arms and interventions
Ivonescimab Plus Pemetrexed and Platinum-Based ChemotherapyExperimental
A single experimental arm consisting of sequential ivonescimab dose-escalation cohorts using a conventional 3+3 design.
Drugs: Ivonescimab Combined With Chemotherapy
Sites
4 sites in 1 country